Medical Innovation Exchange

Axcella misses primary endpoint in long COVID trial but plots path to market based on fatigue scores


Leave a Comment

Your email address will not be published.

Leave the field below empty!

This site uses Akismet to reduce spam. Learn how your comment data is processed.